Abstract
The immunophilin ligands cyclosporin A, FK506 and rapamycin are best known for their immunosuppressive properties and their clinical use in transplantation medicine. These compounds or their analogs are also clinically used or investigated in various types of cancer, coronary angioplasty, dermatology, hepatitis C infections, and neuroprotection. Furthermore, the role of immunophilins in various pathologies is increasingly being recognized, supporting the preclinical drug development for novel immunophilin targets. Finally, immunophilin ligands are widely used as sophisticated tools in chemical biology. This review shows the progress on three major areas made in the last five years. An update of the immunosuppressive ligands and their clinical applications is discussed in the first part of the review, followed by a discussion about the emerging immunophilin targets and their respective ligands. The final section gives a detailed assessment of immunophilin ligand-based tools.
Keywords: FK506, rapamycin, cyclosporin, immunosupressant, chemical dimerizers, immunophilin, neuroprotection, emerging immunophilin, neurobiology, elucidation
Current Medicinal Chemistry
Title: The Chemical Biology of Immunophilin Ligands
Volume: 18 Issue: 35
Author(s): S. Gaali, R. Gopalakrishnan, Y. Wang, C. Kozany and F. Hausch
Affiliation:
Keywords: FK506, rapamycin, cyclosporin, immunosupressant, chemical dimerizers, immunophilin, neuroprotection, emerging immunophilin, neurobiology, elucidation
Abstract: The immunophilin ligands cyclosporin A, FK506 and rapamycin are best known for their immunosuppressive properties and their clinical use in transplantation medicine. These compounds or their analogs are also clinically used or investigated in various types of cancer, coronary angioplasty, dermatology, hepatitis C infections, and neuroprotection. Furthermore, the role of immunophilins in various pathologies is increasingly being recognized, supporting the preclinical drug development for novel immunophilin targets. Finally, immunophilin ligands are widely used as sophisticated tools in chemical biology. This review shows the progress on three major areas made in the last five years. An update of the immunosuppressive ligands and their clinical applications is discussed in the first part of the review, followed by a discussion about the emerging immunophilin targets and their respective ligands. The final section gives a detailed assessment of immunophilin ligand-based tools.
Export Options
About this article
Cite this article as:
Gaali S., Gopalakrishnan R., Wang Y., Kozany C. and Hausch F., The Chemical Biology of Immunophilin Ligands, Current Medicinal Chemistry 2011; 18 (35) . https://dx.doi.org/10.2174/092986711798194342
DOI https://dx.doi.org/10.2174/092986711798194342 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Determinants of Human Coronary Collaterals
Current Cardiology Reviews Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Myocardial Revascularization Strategies in Diabetic Patients with Multi-Vessel Disease: CABG vs DES-Based PCI
Current Pharmaceutical Design Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Reperfusion Therapies for Acute Ischemic Stroke: An Update
Current Cardiology Reviews Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Prognostic Role of miRNAs in Coronary Artery Disease
Current Topics in Medicinal Chemistry Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Current Drug Safety Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology
Current Vascular Pharmacology General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy